Browse CARD14

Summary
SymbolCARD14
Namecaspase recruitment domain family, member 14
Aliases CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cytoplasm ; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm ; SUBCELLULAR LOCATION: Isoform 3: Cytoplasm
Domain PF00619 Caspase recruitment domain
PF00625 Guanylate kinase
Function

Acts as a scaffolding protein that can activate the inflammatory transcription factor NF-kappa-B and p38/JNK MAP kinase signaling pathways. Forms a signaling complex with BCL10 and MALT1, and activates MALT1 proteolytic activity and inflammatory gene expression. MALT1 is indispensable for CARD14-induced activation of NF-kappa-B and p38/JNK MAP kinases (PubMed:11278692, PubMed:21302310, PubMed:27113748, PubMed:27071417). May play a role in signaling mediated by TRAF2, TRAF3 and TRAF6 and protects cells against apoptosis. ; FUNCTION: Isoform 3: Not able to activate the inflammatory transcription factor NF-kappa-B and may fuction as a dominant negative regulator (PubMed:21302310, PubMed:26358359).

> Gene Ontology
 
Biological Process GO:0007250 activation of NF-kappaB-inducing kinase activity
GO:0032147 activation of protein kinase activity
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0033674 positive regulation of kinase activity
GO:0034612 response to tumor necrosis factor
GO:0038061 NIK/NF-kappaB signaling
GO:0045860 positive regulation of protein kinase activity
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0071356 cellular response to tumor necrosis factor
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:1901222 regulation of NIK/NF-kappaB signaling
GO:1901224 positive regulation of NIK/NF-kappaB signaling
Molecular Function GO:0050700 CARD domain binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04064 NF-kappa B signaling pathway
Reactome -
Summary
SymbolCARD14
Namecaspase recruitment domain family, member 14
Aliases CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CARD14 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCARD14
Namecaspase recruitment domain family, member 14
Aliases CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CARD14 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCARD14
Namecaspase recruitment domain family, member 14
Aliases CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CARD14 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.9430.0242
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4110.601
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.3340.0311
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.530.16
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4550.823
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.620.803
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3260.443
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2350.792
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3850.705
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7460.0573
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7590.146
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0720.697
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CARD14 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCARD14
Namecaspase recruitment domain family, member 14
Aliases CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CARD14. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCARD14
Namecaspase recruitment domain family, member 14
Aliases CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CARD14. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CARD14.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCARD14
Namecaspase recruitment domain family, member 14
Aliases CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CARD14. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCARD14
Namecaspase recruitment domain family, member 14
Aliases CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CARD14 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCARD14
Namecaspase recruitment domain family, member 14
Aliases CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CARD14 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCARD14
Namecaspase recruitment domain family, member 14
Aliases CARMA2; BIMP2; PSORS2; psoriasis susceptibility 2; CARD-containing MAGUK protein 2; bcl10-interacting maguk ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CARD14 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.